Merck & Co., Inc. (MRK) Earnings History

8 quarters held2/6 transcripts analyzed3/40 figures attested
Connect your agent
PeriodRevenueYoYNet incomeEPS (dil.)Filed
Q2 2026$16.6B+5.1%$-1.3B$-0.54Aug 4, 2026
LATESTEarnings filing (8-K)10-QFiled Aug 4, 2026, 6:47 AM ET
Earnings call · Aug 4, 2026deck
Q2 FY26YoY6M FY26
Revenue$16.6B+5.1%$32.9B
Net income$-1.3B-130.2%$-5.6B
Op income–––
EPS (dil.)$-0.541-130.7%–
EPS (basic)–––
Gross margin73.5%-4.0pp
Net margin-8.0%-36.0pp
  1. [1] “GAAP) loss / earnings per share (EPS) assuming dilution was a loss per share of $0.54” view source

Guidance & outlook

Management guidance

Q2 2026

fy_current

revenue
$66.3B—$67.3B
other
35—36
eps_diluted
$2.66—$2.76

Special items & operational metrics

Operational metrics

Q2 2026
WINREVAIR
588.0M
+75.0% YoY
Prior year: 336.0M
USD Millions
Animal Health
1775.0M
+7.8% YoY
Prior year: 1646.0M
USD Millions
LIPFENDRA
N/A
USD Millions
KEYTRUDA/KEYTRUDA QLEX
8366.0M
+5.2% YoY
Prior year: 7956.0M
USD Millions
Q1 2026$16.3B+4.9%$-4.2B$-1.72Apr 30, 2026
Earnings filing (8-K)10-QFiled Apr 30, 2026, 6:53 AM ET
Earnings call · Apr 30, 2026transcriptView originalprepared remarksQ&Adeck
Q1 FY26YoY
Revenue$16.3B1+4.9%
Net income$-4.2B-183.5%
Op income––
EPS (dil.)$-1.72-185.6%
EPS (basic)––
Gross margin74.2%-3.8pp
Net margin-26.0%-58.7pp
  1. [1] “Total Worldwide Sales Were $16.3 Billion (5% Growth; 3% Growth ex-FX)” view source
Q4 2025$16.4B+5.0%$3.0B$1.19Feb 3, 2026
Earnings filing (8-K)10-KFiled Feb 3, 2026, 6:38 AM ET
Earnings call · Feb 3, 2026transcriptView originalprepared remarksQ&Adeck
Q4 FY25YoYFY25
Revenue$16.4B+5.0%$65.0B
Net income$3.0B-20.8%$18.3B
Op income–––
EPS (dil.)$1.19-20.3%–
EPS (basic)–––
Gross margin66.2%-9.3pp
Net margin18.1%-5.9pp
Q3 2025$17.3B+4.0%$5.8B$2.32Oct 30, 2025
Earnings filing (8-K)10-QFiled Oct 30, 2025, 6:40 AM ET
Q3 FY25YoY9M FY25
Revenue$17.3B+4.0%–
Net income$5.8B+83.0%$15.3B
Op income–––
EPS (dil.)$2.32+87.0%$6.08
EPS (basic)–––
Gross margin77.7%+2.2pp
Q2 2025$15.8B-2.0%$4.4B$1.76Jul 29, 2025
Earnings filing (8-K)10-QFiled Jul 29, 2025, 6:42 AM ET
Q2 FY25YoY6M FY25
Revenue$15.8B-2.0%–
Net income$4.4B-19.0%$9.5B
Op income–––
EPS (dil.)$1.76-17.8%$3.77
EPS (basic)–––
Gross margin77.5%+0.7pp
Q1 2025$15.5B-1.6%$5.1B$2.01Apr 24, 2025
Earnings filing (8-K)10-QFiled Apr 24, 2025, 6:45 AM ET
Q1 FY25YoY
Revenue$15.5B-1.6%
Net income$5.1B+6.7%
Op income––
EPS (dil.)$2.01+7.5%
EPS (basic)––
Gross margin78.0%+0.4pp
Q4 2024$15.6B+6.8%$3.7B$1.48Feb 4, 2025
Earnings filing (8-K)10-KFiled Feb 4, 2025, 6:45 AM ET
Q4 FY24YoYFY24
Revenue$15.6B+6.8%$64.2B
Net income$3.7B–$17.1B
Op income–––
EPS (dil.)$1.48–$6.74
EPS (basic)–––
Gross margin75.5%+2.2pp
Q3 2024$16.7B+4.4%$3.2B$1.24Oct 31, 2024
Earnings filing (8-K)10-QFiled Oct 31, 2024, 6:44 AM ET
Earnings call · Oct 31, 2024
Q3 FY24YoY9M FY24
Revenue$16.7B1+4.4%$48.5B
Net income$3.2B-33.5%$13.4B
Op income–––
EPS (dil.)$1.24-33.3%$5.26
EPS (basic)–––
Gross margin75.5%+2.2pp
Net margin18.9%-10.8pp
  1. [1] “Sales* 16,657 4” view source

IR event calendar

The IR event calendar could not be fetched at last check (error); events may exist at the source but weren't retrievable.

The IR event calendar could not be fetched at last check (error); events may exist at the source but weren't retrievable.

Filing coverage

53 filings indexed · 102,244 XBRL facts
FilingDatePeriodSectionsTables
10-Q2026-08-07–3149
8-K2026-08-04Q2 202680
8-K2026-05-28–10
8-K2026-05-22–10
10-Q2026-05-04–3055
8-K2026-04-30Q1 202680
DEF 14A2026-04-08–200
10-K2026-02-24–5490
8-K2026-02-03Q4 202570
8-K2025-12-04–20

Showing the latest 10 of 53 — the full set is in the API.

Related Research

Analysis

The $15 Billion Earnings Illusion Behind AbbVie's 96x P/E

Analysis

Boston Scientific Hit a ROIC Inflection — Then Bet $14.5B on Penumbra

Analysis

The $1.7B Hidden Cost of Stryker's Acquisition Machine